183results about "Reverse transcribing DNA viruses" patented technology

Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

The invention discloses a virus-like structure nano adapter and application thereof, on the basis of hepatitis B virus core protein Uniprot P03146 of which nucleic acid binding domains at 145-183 sites of a C tail end are removed, CBP as shown in SEQ ID NO.01 is respectively inserted into a spike part and an N tail end of the hepatitis B virus core protein Uniprot P03146. The invention is constructed based on collagen combined polypeptide CBP designed by bionic decorrin, aims to imitate the interaction between natural decorrin and collagenous fiber, can efficiently cross over corneal epithelium barrier and repair corneal stroma in a non-photo-crosslinking manner, and solves the limitation of existing clinical treatment.

The invention relates to the technical field of biological medicines, in particular to a vaccine for treating or preventing hepatitis B virus infection. The vaccine comprises a hepatitis B surface antigen and a composite adjuvant, wherein the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21, and the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21; the nucleotide sequence of the CpG oligodeoxynucleotide is as shown in SEQ ID NO. 1. According to the vaccine provided by the invention, an HBsAg antibody can be generated in a normal mouse body, and HBV in an HBV-carrier mouse can be effectively eliminated, so that the vaccine has the effect of treating or preventing hepatitis B virus infection. According to the vaccine provided by the invention, two adjuvants, namely CpG oligodeoxynucleotide and saponin QS-21, are adopted, so that the vaccine can be used for synergistically activating an immune effect, enhancing the activation of B cells and permanently transforming into plasma cells, and meanwhile, the vaccine can be used for resisting immune tolerance of T cells, realizing the removal of hepatitis B viruses and realizing functional cure of clinical hepatitis B treatment.

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

The invention belongs to the field of biological medicines, and particularly relates to an antigen-antibody compound for enhancing immune response of hepatitis B patients as well as a preparation method and application of the antigen-antibody compound. The antigen-antibody compound preparation prepared from the HBsAg and the anti-HBsAg monoclonal antibody is superior to an antigen-antibody compound preparation prepared from a polyclonal antibody in the aspect of continuously inducing the immune response of a chronic hepatitis B patient, and an antigen-antibody compound for inducing the immune response of the hepatitis B patient is developed for the first time; in the compound, the hepatitis B surface antigen is combined with the anti-HBsAg monoclonal antibody, and the compound formed by the hepatitis B surface antigen and the anti-HBsAg monoclonal antibody in a certain mass ratio can induce immune response of chronic hepatitis B patients and can also prevent and / or treat chronic hepatitis B.

The invention belongs to the technical field of biological medicines, and particularly relates to an mRNA vaccine for preventing or treating hepatitis B virus infection and application of the mRNA vaccine. The mRNA vaccine comprises mRNA for coding hepatitis B virus surface antigen or / and hepatitis B virus core associated antigen or / and hepatitis B virus front surface antigen 1 fusion IgG Fc segment protein, and the mRNA is wrapped by lipid nanoparticles to form a delivery system to be prepared into the mRNA vaccine. The vaccine preparation can specifically enhance humoral immune response and cellular immune response aiming at hepatitis B virus surface antigen or / and hepatitis B virus core related antigen or / and hepatitis B virus front surface antigen, and can be used for preventing and treating hepatitis B. All the components in the vaccine preparation can be widely obtained, the vaccine cost is effectively reduced, the vaccine yield is increased, and therefore the vaccine preparation has good practical application value.

The present invention pertains to the field of pharmaceutical technology. Specifically, the present invention relates to a zinc risedronate micro / nano adjuvant with sustained-release function formed by mineralization of zinc ions and risedronic acid as main components and its use as a vaccine adjuvant. The present invention also relates to a method for preparing zinc risedronate micro / nano adjuvant. The present invention also relates to a chemical composition, vaccine adjuvant and vaccine composition comprising zinc risedronate micro / nano adjuvant. The present invention also relates to a use of zinc risedronate micro / nano adjuvant as a vaccine adjuvant.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The invention provides a nucleic acid molecule. The nucleic acid molecule comprises a nucleic acid sequence as shown in SEQ ID NO.2. The invention also provides a polypeptide which is encoded by the nucleic acid molecule. The invention further provides a recombinant plasmid, and the recombinant plasmid comprises the nucleic acid molecule. The invention also provides a preparation method of the recombinant protein. The preparation method comprises the following steps: optimizing an HBc gene into a nucleotide sequence comprising SEQ ID NO.2; constructing a recombinant plasmid based on the nucleic acid sequence; the recombinant plasmid is transfected into an HEK293 cell for expression; the cell supernatant is collected for purification of the recombinant protein. The HBc gene is optimized according to the codon preference of the HEK293 cell, and the codon adaptation index (CAI) value of the HBc gene is increased to 0.930. The expression system established by the invention has the remarkable characteristics of high efficiency and low pollution, not only overcomes the defects of the traditional expression system, but also provides a brand new strategy and technical support for efficient production of vaccines and development of nano-carriers.

The invention discloses a GNRH-I-MS2 fusion protein, a castrated MS2 virus-like particle subunit vaccine and a preparation method of the castrated MS2 virus-like particle subunit vaccine.

The invention relates to a GnRH-I-M1 recombinant protein. A vaccine prepared from the GnRH-I-M1 recombinant protein is high in antigen purity and good in safety, and has a good castration effect.

Disclosed herein is a method for enhancing immune response of a vaccine. The method includes preparing a Phycocyanin compound. The Phycocyanin compound includes at least one of C-phycocyanin (C-PC), Phycoerythrin (PE), Allophycocyanin (APC), phycocyanobilin (PCB), and combinations thereof. The method further includes administering the prepared Phycocyanin along with a vaccine composition to a living body.

The present invention relates to vaccine compositions, most notably vaccine compositions wherein the antigenic component is large, for example over 50 kDa, or multimeric, i.e. comprised of subunits. Such antigenic components are of particular interest, because they may represent antigenic components from pathogens that currently it is not possible to vaccinate against. The invention relates to a composition comprising a particle displaying an antigenic component, wherein said composition comprises an antigenic component comprising a first peptide tag, and a moiety comprising a second peptide tag, wherein the antigenic component and the moiety are linked via an isopeptide bond between said first and second peptide tags, and wherein the antigenic component is over 50 kDa, or alternatively is multimeric.

The invention discloses a polyantigen and a preparation method thereof. Wherein the polyantigen is formed by self-assembly of fusion protein, and the fusion protein comprises capsid protein and C-reactive protein. The multi-antigen is of a virus-like particle structure, wherein the C-reactive protein is located on the outer side of the virus-like particle structure. The polymer antigen is an icosahedron polymer particle, partially simulates spatial sites of a natural antigen pentamer, and improves the recognition efficiency of the generated antibody on the natural antigen.

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

The invention provides a construction method of an HBV (Hepatitis B Virus) infection model based on multilineage hepatobiliary organs, which comprises the following steps: differentiating human pluripotent stem cells to form immune cell-containing hepatobiliary organs for further maturation culture, and enabling the hepatobiliary organs to be mature in function and highly express NTCP (Natriuretic Therapeutic Cells) by using a maturation culture medium containing bile metabolism substrate cholesterol and deoxybear bile acid, so as to obtain the HBV infection model based on the multilineage hepatobiliary organs. And then infecting the mature organs by adopting an HBV virus strain generated by HepAD38 cells to construct an in-vitro model which is susceptible to HBV and can maintain an infection state for a long time. According to the construction method, the liver infection and immune interaction microenvironment can be simulated more truly, and a stable and reliable experimental platform is provided for HBV infection mechanism research and anti-HBV drug screening.

Relates to the technical field of biology, in particular to a castrated PapMV virus-like particle subunit vaccine and a preparation method thereof. The invention provides the GnRH-I-PapMV recombinant protein which is high in purity and good in specificity. The vaccine prepared from the GnRH-I-PapMV recombinant protein is high in antigen purity, good in safety and good in castration effect.

Relates to the technical field of biology, in particular to a castrated HBsAg virus-like particle subunit vaccine and a preparation method thereof. The invention provides the GnRH-I-HBsAg recombinant protein which is high in purity and good in specificity. The vaccine prepared from the GnRH-I-HBsAg recombinant protein is high in antigen purity and good in safety, and has a good castration effect.

Provided herein are polypeptides, nucleic acids, and cells comprising antigen-binding domains that specifically bind to Solute Carrier Family 34 Member 2 (SLC34A2) or Transmembrane protease, serine 4 (TMPRSS4), and methods of use thereof. Also provided are polypeptides, systems, nucleic acids, and cells comprising priming receptors comprising an antigen-binding domain that specifically binds Solute Carrier Family 34 Member 2 (SLC34A2) and chimeric antigen receptors (CAR) comprising an antigen-binding domain that specifically binds to Transmembrane protease, serine 4 (TMPRSS4).

The invention relates to a castrated TMV virus-like particle subunit vaccine and a preparation method thereof. The GnRH-I-TMV recombinant protein is high in purity and good in specificity. A vaccine prepared from the GnRH-I-TMV recombinant protein is high in antigen purity, good in safety and good in castration effect.

Provided herein are methods for administering hepatitis B virus surface antigen (HBsAg) to a subject suffering from chronic hepatitis B to differentiate between responder subjects and non-responder subjects that the administration of HBsAg results in an increased response to HBV antibody levels, and treating chronic hepatitis B in responder subjects using HBV therapy. Also provided are methods of excluding unresponded subjects outside a clinical study.

The present disclosure provides compositions and methods useful for inducing a Th1 cell response in a subject suffering from Hepatitis B. As described herein, the compositions of the disclosure comprise HBsAg having S, Pre-S1 and Pre-S2 proteins and an aluminum phosphate adjuvant. In a preferred embodiment, the immunogenic composition comprises at least 20 μg / ml of HBsAg antigen and the amount of non-adsorbed antigen is at least 30%.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

The present invention provides novel immunogenic peptides derived from the X and polymerase proteins of hepatitis B virus (HBV). These peptides contain epitopes that are well conserved among multiple HBV variants and are derived from regions of the proteins essential for viral replication. Furthermore, these novel HBV antigens bind to multiple HLA types and induce IFN-glucan synthesis in PBMCs from HBV-resolved individuals. γ Epitopes that elicit a response were identified.

The present disclosure provides isolated polynucleotides comprising multiple coding regions that are linked. In some aspects, a polynucleotide comprises at least a first coding region encoding a first antigen and a second coding region encoding a second antigen, wherein the first antigen and the second antigen are not the same, and wherein the first coding region and the second coding region are linked. The present disclosure also relates to the use of such polynucleotides to express multiple antigens in a cell and to induce multi-antigen-specific immune response in vivo.

A chimeric antigen receptor (CAR), for example a CD19-specific CAR, capable of targeting an antigen expressed on disease-associated cells, such as tumor cells. A polynucleotide encoding the CAR and, optionally: i) an miRNA silencer module capable of inhibiting the expression of an immune checkpoint protein (e.g., PD-1); ii) a cytokine (e.g., membrane-bound IL-15); and / or a cell tag (e.g., a HER-1 kill switch). A vector comprising the polynucleotide. A modified immune effector cell comprising the CAR, polynucleotide, or vector. Compositions and kits comprising the CAR, polynucleotide, vector, and / or modified immune effector cell. Use of the CAR, polynucleotide, vector, and / or modified immune effector cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for treating a subject with a disease or disorder, comprising administering the CAR, polynucleotide, vector, and / or modified immune effector cell to a subject in need thereof.

The present invention relates to compositions and methods for therapeutic immunization for treatment of chronic hepatitis B virus (CHB). Methods of the invention include a method generating a high titer hybrid-hepatitis B virus (HBV) vector, methods of treating and / or preventing HBV infection and / or CHB, and methods of inducing a memory T and B cell immune response against HBV infection in a subject administered the VLV composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a subject to protect the subject against infection with HBV.

Pharmaceutical compositions comprising a 4-sulfamoyl-heteroaryl-2-carboxamides that are useful as pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions are disclosed herein.

Provided are affinity ligands that bind to Hepatitis B surface antigen (HBsAg), affinity resins comprising the HBsAg-binding ligands, and related compositions and methods for the isolation and / or purification of HBsAg.